Enterprise Value
67.92M
Cash
44.56M
Avg Qtr Burn
-329.5K
Short % of Float
10.02%
Insider Ownership
9.77%
Institutional Own.
13.90%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ELFABRIO (Pegunigalsidase alfa )(PRX-102) Details Genetic disorder, Rare genetic disease | Approved Update | |
Elelyso® (taliglucerase alpha) Details Genetic disorder, Rare genetic disease | Approved Quarterly sales | |
PRX-115 Details Chronic refractory gout | Phase 1 Data readout | |
Alidornase alfa (PRX-110) Details Genetic disorder, Rare genetic disease, Cystic fibrosis | Failed Discontinued | |
OPRX-106 Details Inflammatory disease, Bowel disorder | Failed Discontinued |